Literature DB >> 14580232

Hyperekplexia (startle disease): a novel mutation (S270T) in the M2 domain of the GLRA1 gene and a molecular review of the disorder.

Pablo Lapunzina1, Juan M Sánchez, Marta Cabrera, Ana Moreno, Alicia Delicado, Maria L de Torres, Angeles M Mori, José Quero, Isidora Lopez Pajares.   

Abstract

BACKGROUND: We report on a novel mutation (S270T) in the M2 domain of the GLRA1 (alpha subunit of the glycine receptor) gene causing autosomal dominant hyperekplexia in a neonate, the mother and maternal uncle. All affected members showed the typical clinical features of the disorder. This novel S270T (T1188A) mutation is located in the boundary of the transmembrane M2 domain of the GLRA1 protein, close to other previously reported mutations. Mutations in this 'hot spot' domain of GLRA1 are frequent in autosomal dominant hyperekplexia but are not usually seen in the autosomal recessive form of the disease in which both the M1 and the carboxy terminal domains have been implicated.
METHODS: Genomic DNA was extracted by standard procedures from peripheral blood leukocytes and exon 6 of the GLRA1 gene was amplified using primers and PCR conditions. A complete sequence analysis of the fragment was performed. DNA sequences were analyzed both by direct observation of the electropherogram and by comparison with the published sequence.
RESULTS: The proband had metabolic acidosis, which was probably related to continuous contractions of somatic muscles and intractable hypertonia. Data seem to show a direct relationship between the mechanism of inheritance of the disorder and the location of the molecular defect. The patients showed almost all the clinical signs of hyperekplexia: exaggerated startle response, muscle hypertonia in response to unexpected tactile and/or auditory stimuli, hyperexcitability, and sudden falls.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14580232     DOI: 10.1007/BF03260028

Source DB:  PubMed          Journal:  Mol Diagn        ISSN: 1084-8592


  28 in total

1.  High prevalence of KatG Ser315Thr substitution among isoniazid-resistant Mycobacterium tuberculosis clinical isolates from northwestern Russia, 1996 to 2001.

Authors:  Igor Mokrousov; Olga Narvskaya; Tatiana Otten; Elena Limeschenko; Lidia Steklova; Boris Vyshnevskiy
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

2.  A GLRA1 null mutation in recessive hyperekplexia challenges the functional role of glycine receptors.

Authors:  W Brune; R G Weber; B Saul; M von Knebel Doeberitz; C Grond-Ginsbach; K Kellerman; H M Meinck; C M Becker
Journal:  Am J Hum Genet       Date:  1996-05       Impact factor: 11.025

3.  Identification of a novel point mutation (S65T) in alpha-galactosidase A gene in Chinese patients with Fabry disease. Mutations in brief no. 169. Online.

Authors:  C H Chen; P W Shyu; S J Wu; S S Sheu; R J Desnick; K J Hsiao
Journal:  Hum Mutat       Date:  1998       Impact factor: 4.878

Review 4.  The glycine receptor.

Authors:  S Rajendra; J W Lynch; P R Schofield
Journal:  Pharmacol Ther       Date:  1997       Impact factor: 12.310

5.  Startle responses in hereditary hyperekplexia.

Authors:  M A Tijssen; L M Voorkamp; G W Padberg; J G van Dijk
Journal:  Arch Neurol       Date:  1997-04

Review 6.  Disorders of membrane channels or channelopathies.

Authors:  G G Celesia
Journal:  Clin Neurophysiol       Date:  2001-01       Impact factor: 3.708

7.  Hyperekplexia associated with compound heterozygote mutations in the beta-subunit of the human inhibitory glycine receptor (GLRB).

Authors:  Mark I Rees; Trevor M Lewis; John B J Kwok; Geert R Mortier; Paul Govaert; Russell G Snell; Peter R Schofield; Michael J Owen
Journal:  Hum Mol Genet       Date:  2002-04-01       Impact factor: 6.150

8.  Mutations in the glycine receptor alpha1 subunit (GLRA1) gene in hereditary hyperekplexia pedigrees: evidence for non-penetrance of mutation Y279C.

Authors:  J B Kwok; S Raskin; G Morgan; S A Antoniuk; I Bruk; P R Schofield
Journal:  J Med Genet       Date:  2001-06       Impact factor: 6.318

9.  Compound heterozygosity and nonsense mutations in the alpha(1)-subunit of the inhibitory glycine receptor in hyperekplexia.

Authors:  M I Rees; T M Lewis; B Vafa; C Ferrie; P Corry; F Muntoni; H Jungbluth; J B Stephenson; M Kerr; R G Snell; P R Schofield; M J Owen
Journal:  Hum Genet       Date:  2001-09       Impact factor: 4.132

10.  The human glycine receptor beta subunit gene (GLRB): structure, refined chromosomal localization, and population polymorphism.

Authors:  N Milani; C Mülhardt; R G Weber; P Lichter; P Kioschis; A Poustka; C M Becker
Journal:  Genomics       Date:  1998-06-15       Impact factor: 5.736

View more
  6 in total

1.  A novel nonsense autosomal dominant mutation in the GLRA1 gene causing hyperekplexia.

Authors:  Ivan Milenkovic; Alexander Zimprich; Martin Gencik; Kirsten Platho-Elwischger; Stefan Seidel
Journal:  J Neural Transm (Vienna)       Date:  2018-09-04       Impact factor: 3.575

2.  Hereditary hyperekplexia caused by novel mutations of GLRA1 in Turkish families.

Authors:  Sandra L Gilbert; Fatih Ozdag; Umit H Ulas; William B Dobyns; Bruce T Lahn
Journal:  Mol Diagn       Date:  2004

Review 3.  Glycine receptor mouse mutants: model systems for human hyperekplexia.

Authors:  Natascha Schaefer; Georg Langlhofer; Christoph J Kluck; Carmen Villmann
Journal:  Br J Pharmacol       Date:  2013-11       Impact factor: 8.739

Review 4.  The impact of human hyperekplexia mutations on glycine receptor structure and function.

Authors:  Anna Bode; Joseph W Lynch
Journal:  Mol Brain       Date:  2014-01-09       Impact factor: 4.041

5.  The startle disease mutation α1S270T predicts shortening of glycinergic synaptic currents.

Authors:  Zhiyi Wu; Remigijus Lape; Lea Jopp-Saile; Benjamin J O'Callaghan; Timo Greiner; Lucia G Sivilotti
Journal:  J Physiol       Date:  2020-06-18       Impact factor: 5.182

Review 6.  Impaired Glycine Receptor Trafficking in Neurological Diseases.

Authors:  Natascha Schaefer; Vera Roemer; Dieter Janzen; Carmen Villmann
Journal:  Front Mol Neurosci       Date:  2018-08-21       Impact factor: 5.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.